| Literature DB >> 35656401 |
Wenke Cheng1, Lili Wang2,3, Siwei Chen4.
Abstract
Background: Several previous studies have reported that dyslipidemia is associated with the risk of hypertension, but these studies are mainly conducted in European and US populations, with a very few studies in the Asian population. Moreover, the effects of atherosclerotic indices, including atherogenic coefficient (AC) and atherogenic risk of plasma (AIP), on hypertension in Asians have not been well described so far.Entities:
Keywords: Bayesian network model; high-density lipoprotein cholesterol; hypertension; lipid; low density lipoprotein; total cholesterol; triglycerides
Year: 2022 PMID: 35656401 PMCID: PMC9152277 DOI: 10.3389/fcvm.2022.887067
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
Figure 1The flowchart of the study. The first part is the flowchart of the original study and the second part is the flowchart of the current study.
Baseline information of the overall population .
|
|
|
|
| |
|---|---|---|---|---|
| Age (years) | 41 (34–53) | 39 (33–50) | 53 (41–63) | <0.001 |
| Female (%) | 54,099 (46.2) | 48,304 (48.5) | 5,795 (33.1) | <0.001 |
| Current smoker (%) | 6,674 (5.7) | 5,520 (5.5) | 1,154 (6.6) | <0.001 |
| Current drinker (%) | 872 (0.7) | 651 (0.6) | 221 (1.3) | <0.001 |
| Family history of diabetes (%) | 2,651 (2.3) | 2,367 (2.4) | 284 (1.6) | <0.001 |
| BMI (kg/m2) | 23.2 (21–25.5) | 22.9 (20.8–25.1) | 25.1 (23–27.3) | <0.001 |
| FPG (mmol/L) | 5.0 (4.61–5.35) | 4.95 (4.6–5.3) | 5.19 (4.8–5.62) | <0.001 |
| ALT (U/L) | 18.2 (13–27.8) | 18 (12.9–26.8) | 22 (15.7–33) | <0.001 |
| AST (U/L) | 22.0 (18.7–26.9) | 21.8 (18.2–26) | 24.2 (20.7–29.7) | <0.001 |
| BUN (mmol/L) | 4.57 (3.85–5.4) | 4.53 (3.81–5.35) | 4.78 (4.06–5.63) | <0.001 |
| Scr (μmol/L) | 71.3 (59.3–83.0) | 70.5 (58.8–82.4) | 75.8 (64.23–86.0) | <0.001 |
|
| ||||
| TC (mg/dl) | 181.70 (159.67–204.90) | 179.77 (158.51–202.97) | 191.75 (168.56–216.50) | <0.001 |
| TG (mg/dl) | 97.46 (67.34–146.19) | 97.46 (67.34–146.19) | 97.46 (67.34–147.08) | 0.772 |
| LDL (mg/dl) | 104.38 (88.53–121.78) | 103.22 (87.76–120.62) | 110.95 (93.94–128.74) | <0.001 |
| HDL-c (mg/dl) | 51.80 (45.23–59.92) | 52.19 (45.23–59.92) | 51.42 (44.46–59.15) | <0.001 |
| Non-HDL-c (mg/dl) | 127.96 (108.25–151.16) | 126.03 (106.70–148.84) | 138.40 (117.53–162.37) | <0.001 |
| AC | 2.43 (1.95–3.1) | 2.38 (1.91–3.04) | 2.72 (2.21–3.46) | <0.001 |
| AIP | 0.28 (0.1–0.47) | 0.28 (0.10–0.46) | 0.29 (0.11–0.48) | <0.001 |
Continuous data are expressed as median (interquartile range) due to the skewed distribution. The p-value is a comparison between the normotension and hypertension groups. FPG, fasting plasma glucose; TG, triglycerides; TC, total cholesterol; HDL-c, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; AC, atherogenic coefficient; AIP, atherogenic risk of plasma; Scr, serum creatinine; BUN, blood urea nitrogen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index.
Subgroup analysis of differences in lipid profiles and atherosclerotic indices between normotension and hypertension according to gender, age, BMI, AST, and ALT.
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
|
|
|
| ||||
| TC (mg/dl) | 181.70 (160.05–204.90) | 189.43 (167.40–212.63) | <0.001 | 177.84 (158.12–201.80) | 199.87 (175.90–225.77) | <0.001 |
| TG (mg/dl) | 97.46 (67.34–147.96) | 97.46 (66.45–147.08) | 0.274 | 97.46 (68.22–146.19) | 99.23 (67.34–147.08) | 0.319 |
| LDL (mg/dl) | 104.77 (88.92–122.17) | 109.02 (92.78–126.80) | <0.001 | 101.29 (86.21–119.07) | 115.59 (98.58–134.54) | <0.001 |
| HDL–c (mg/dl) | 49.1 (42.14–56.44) | 49.1 (42.14–56.83) | 0.073 | 56.06 (48.71–64.18) | 54.51 (47.17–62.63) | <0.001 |
| Non–HDL–c (mg/dl) | 131.06 (110.95–154.64) | 139.18 (118.30–162.37) | <0.001 | 120.62 (102.06–143.43) | 143.82 (121.59–169.33) | <0.001 |
| AC | 2.64 (2.12–3.38) | 2.77 (2.25–3.56) | <0.001 | 2.15 (1.74–2.68) | 2.62 (2.14–3.25) | <0.001 |
| AIP | 0.31 (0.13–0.49) | 0.30 (0.13–0.49) | 0.148 | 0.25 (0.07–0.43) | 0.26 (0.09–0.45) | <0.001 |
|
|
| |||||
| TC (mg/dl) | 177.84 (158.12–201.03) | 189.43 (167.01–212.63) | <0.001 | 197.16 (173.97–222.68) | 199.49 (175.90–224.61) | <0.001 |
| TG (mg/dl) | 97.46 (67.34–147.08) | 97.46 (67.34–145.30) | 0.267 | 97.46 (67.34–147.08) | 98.35 (67.34–148.85) | 0.349 |
| LDL (mg/dl) | 101.68 (86.60–119.07) | 109.02 (92.40–126.80) | <0.001 | 114.82 (97.42–134.15) | 115.59 (98.58–134.54) | 0.074 |
| HDL-c (mg/dl) | 52.19 (45.23–60.70) | 50.64 (43.30–58.38) | <0.001 | 52.58 (44.85–61.08) | 51.80 (44.07–60.50) | 0.002 |
| Non-HDL-c (mg/dl) | 124.10 (105.15–146.91) | 137.63 (116.37–160.83) | <0.001 | 143.82 (121.39–167.40) | 146.33 (124.48–170.49) | <0.001 |
| AC | 2.34 (1.88–2.99) | 2.67 (2.18–3.43) | <0.001 | 2.72 (2.18–3.42) | 2.81 (2.26–3.5) | <0.001 |
| AIP | 0.28 (0.1–0.46) | 0.29 (0.12–0.48) | <0.001 | 0.27 (0.1–0.46) | 0.28 (0.11–0.47) | 0.04 |
|
|
| |||||
| TC (mg/dl) | 174.36 (154.64–197.17) | 189.43 (166.24–214.95) | <0.001 | 185.57 (164.31–209.54) | 193.69 (171.26–218.04) | <0.001 |
| TG (mg/dl) | 97.46 (67.34–147.08) | 97.46 (66.45–147.96) | 0.820 | 97.46 (67.34–147.08) | 97.46 (67.34–146.19) | 0.799 |
| LDL (mg/dl) | 99.36 (84.67–115.98) | 109.02 (92.01–127.19) | <0.001 | 107.47 (91.62–125.65) | 112.11 (95.49–130.28) | <0.001 |
| HDL-c (mg/dl) | 55.28 (47.94–63.40) | 54.90 (47.17–62.63) | 0.007 | 49.48 (42.53–56.83) | 49.87 (42.53–57.60) | <0.001 |
| Non-HDL-c (mg/dl) | 117.91 (100.13–139.56) | 133.38 (112.11–156.57) | <0.001 | 135.31 (114.82–158.51) | 143.04 (121.78–166.62) | <0.001 |
| AC | 2.34 (1.88–2.99) | 2.67 (2.18–3.44) | <0.001 | 2.72 (2.18–3.42) | 2.81 (2.27–3.5) | <0.001 |
| AIP | 0.28 (0.10–0.46) | 0.29 (0.12–0.48) | <0.001 | 0.27 (0.1–0.46) | 0.28 (0.11–0.47) | 0.04 |
|
|
| |||||
| TC (mg/dl) | 179.0 (158.51–202.19) | 190.98 (167.34–216.50) | <0.001 | 189.43 (166.24–215.72) | 197.36 (173.97–227.13) | <0.001 |
| TG (mg/dl) | 97.46 (67.34–146.19) | 97.46 (67.34–147.08) | 0.583 | 97.46 (67.34–143.98) | 98.35 (69.11–150.62) | 0.201 |
| LDL (mg/dl) | 102.84 (87.76–120.23) | 110.57 (93.94–128.35) | <0.001 | 107.86 (91.24–127.96) | 114.63 (95.49–135.31) | <0.001 |
| HDL-c (mg/dl) | 52.19 (45.61–60.31) | 51.80 (44.85–59.15) | <0.001 | 50.26 (42.91–57.99) | 51.03 (43.30–57.99) | 0.510 |
| Non-HDL-c (mg/dl) | 125.26 (106.32–148.45) | 138.02 (116.75–161.60) | <0.001 | 138.01 (114.43–162.76) | 146.33 (126.03–173.0) | <0.001 |
| AC | 2.37 (1.94–2.95) | 2.62 (2.19–3.25) | <0.001 | 2.68 (2.16–3.48) | 2.84 (2.39–3.61) | <0.001 |
| AIP | 0.27 (0.10–0.46) | 0.28 (0.11–0.47) | 0.004 | 0.29 (0.12–0.48) | 0.31 (0.13–0.50) | 0.263 |
|
|
| |||||
| TC (mg/dl) | 178.22 (158.51–201.42) | 192.14 (169.33–216.50) | <0.001 | 192.14 (169.72–216.50) | 197.55 (175.90–222.68) | <0.001 |
| TG (mg/dl) | 178.22 (158.51–201.12) | 192.14 (169.33–216.50) | 0.547 | 97.46 (67.34–145.30) | 97.46 (69.11–143.53) | 0.540 |
| LDL (mg/dl) | 102.06 (86.99–119.46) | 110.57 (94.33–128.74) | <0.001 | 110.58 (93.94–129.51) | 114.43 (96.65–132.99) | <0.001 |
| HDL–c (mg/dl) | 52.58 (45.62–61.08) | 51.42 (44.07–59.54) | <0.001 | 47.94 (40.98–55.67) | 48.32 (40.98–56.06) | 0.411 |
| Non–HDL–c (mg/dl) | 124.49 (105.16–147.29) | 139.18 (117.91–162.76) | <0.001 | 142.66 (120.62–167.40) | 148.45 (127.0–172.42) | <0.001 |
| AC | 2.33 (1.87–2.95) | 2.67 (2.17–3.37) | <0.001 | 2.92 (2.32–3.80) | 3.0 (2.43–3.93) | <0.001 |
| AIP | 0.27 (0.1–0.46) | 0.28 (0.11–0.47) | <0.001 | 0.31 (0.14–0.50) | 0.31 (0.14–0.5) | 0.764 |
Continuous data are expressed as median (interquartile range) due to the skewed distribution. TG, triglycerides; TC, total cholesterol; HDL–c, high–density lipoprotein cholesterol; LDL, low–density lipoprotein cholesterol; AC, atherogenic coefficient; AIP, atherogenic risk of plasma; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index.
Multivariable logistic regression model evaluating the association between serum lipid levels and hypertension.
|
|
|
| ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
| ||||||
| Q 1 ( ≤ 67.3 mg/dl) | Ref | |||||
| Q 2 (67.3–97.5 mg/dl) | 0.967 (0.923–1.012) | 0.149 | 0.979 (0.932–1.028) | 0.394 | 0.960 (0.889–1.037) | 0.296 |
| Q 3 (97.5–147.1 mg/dl) | 0.995 (0.951–1.040) | 0.822 | 0.993 (0.947–1.042) | 0.781 | 1.007 (0.934–1.085) | 0.862 |
| Q 4 (≥147.1 mg/dl) | 0.984 (0.940–1.029) | 0.478 | 0.979 (0.933–1.027) | 0.378 | 0.993 (0.920–1.071) | 0.849 |
| Per 1 mg/dl increase | 1.000 (1.000–1.000) | 0.624 | 1.000 (1.000–1.000) | 0.938 | 1.000 (1.000–1.000) | 0.160 |
| 0.767 | 0.512 | 0.844 | ||||
|
| ||||||
| Q 1 ( ≤ 160.4 mg/dl) | Ref | |||||
| Q 2 (160.4–181.7 mg/dl) | 1.355 (1.286–1.428) | <0.001 | 1.178 (1.115–1.245) | <0.001 | 0.979 (0.901–1.065) | 0.31 |
| Q 3 (181.7–205.7 mg/dl) | 1.821 (1.733–1.913) | <0.001 | 1.382 (1.312–1.457) | <0.001 | 1.093 (1.008–1.184) | 0.013 |
| Q 4 (≥205.7 mg/dl) | 2.529 (2.411–2.653) | <0.001 | 1.561 (1.483–1.643) | <0.001 | 1.105 (1.021–1.196) | <0.001 |
| Per 1 mg/dl increase | 1.010 (1.009–1.010) | <0.001 | 1.005 (1.004–1.006) | <0.001 | 1.002 (1.001–1.003) | <0.001 |
| <0.001 | <0.001 | <0.001 | ||||
|
| ||||||
| Q 1 ( ≤ 88.5 mg/dl) | Ref | |||||
| Q 2 (67.3–104.4 mg/dl) | 1.322 (1.257–1.391) | <0.001 | 1.143 (1.083–1.206) | <0.001 | 0.979 (0.901–1.065) | 0.625 |
| Q 3 (104.4–122.2 mg/dl) | 1.671 (1.592–1.755) | <0.001 | 1.283 (1.218–1.351) | <0.001 | 1.093 (1.008–1.184) | 0.031 |
| Q 4 (≥122.2 mg/dl) | 2.208 (2.107–2.314) | <0.001 | 1.402 (1.334–1.475) | <0.001 | 1.105 (1.021–1.196) | 0.013 |
| Per 1 mg/dl increase | 1.010 (1.009–1.011) | 1.005 (1.004–1.006) | 1.002 (1.001–1.003) | <0.001 | ||
| <0.001 | <0.001 | 0.001 | ||||
|
| ||||||
| Q 1 ( ≤ 44.8 mg/dl) | Ref | |||||
| Q 2 (44.8–52.2 mg/dl) | 0.838 (0.801–0.875) | <0.001 | 0.948 (0.904–0.994) | 0.026 | 1.091 (1.012–1.176) | 0.023 |
| Q 3 (52.2–60.3 mg/dl) | 0.801 (0.7666–0.837) | <0.001 | 0.947 (0.903–0.994) | 0.026 | 1.194 (1.107–1.288) | <0.001 |
| Q 4 (≥60.3 mg/dl) | 0.719 (0.687–0.752) | <0.001 | 0.877 (0.835–0.922) | <0.001 | 1.192 (1.100–1.292) | <0.001 |
| Per 1 mg/dl increase | 0.989 (0.988–0.990) | <0.001 | 0.995 (0.994–0.997) | <0.001 | 1.006 (1.003–1.008) | <0.001 |
| <0.001 | <0.001 | <0.001 | ||||
|
| ||||||
| Q 1 ( ≤ 107.9 mg/dl) | Ref | |||||
| Q 2 (107.9–128 mg/dl) | 1.558 (1.476–1.664) | <0.001 | 1.267 (1.197–1.341) | <0.001 | 1.042 (0.955–1.137) | 0.354 |
| Q 3 (128–152.3 mg/dl) | 2.186 (2.077–2.301) | <0.001 | 1.485 (1.407–1.568) | <0.001 | 1.144 (1.052–1.244) | 0.002 |
| Q 4 (≥152.3 mg/dl) | 3.059 (2.911–3.214) | <0.001 | 1.708 (1.620–1.8) | <0.001 | 1.148 (1.056–1.248) | 0.001 |
| Per 1 mg/dl increase | 1.011 (1.010–1.012) | <0.001 | 1.006 (1.005–1.007) | <0.001 | 1.002 (1.001–1.003) | <0.001 |
| <0.001 | <0.001 | <0.001 | ||||
|
| ||||||
| Q 1 ( ≤ 1.95) | Ref | Ref | Ref | |||
| Q 2 (1.95–2.43) | 1.756 (1.664–1.853) | <0.001 | 1.428 (1.350–1.511) | <0.001 | 1.193 (1.091–1.305) | <0.001 |
| Q 3 (2.43–3.10) | 2.373 (2.253–2.498) | <0.001 | 1.595 (1.510–1.685) | <0.001 | 1.205 (1.104–1.315) | <0.001 |
| Q 4 (≥3.10) | 2.962 (2.816–3.115) | <0.001 | 1.712 (1.621–1.807) | <0.001 | 1.084 (0.99–1.187) | 0.083 |
| Per 1-unit increase | 1.350 (1.331–1.370) | <0.001 | 1.148 (1.130–1.167) | <0.001 | 0.981 (0.954–1.009) | 0.178 |
| <0.001 | <0.001 | 0.459 | ||||
|
| ||||||
| Q 1 ( ≤ 0.104) | Ref | Ref | Ref | |||
| Q 2 (0.104–0.279) | 1.073 (1.025–1.124) | 0.003 | 1.038 (0.989–1.091) | 0.131 | 1.012 (0.937–1.093) | 0.757 |
| Q 3 (0.279–0.466) | 1.099 (1.050–1.151) | <0.001 | 1.037 (0.988–1.090) | 0.141 | 0.990 (0.917–1.069) | 0.805 |
| Q 4 (≥0.466) | 1.128 (1.077–1.180) | <0.001 | 1.042 (0.992–1.094) | 0.10 | 0.971 (0.899–1.049) | 0.453 |
| Per 0.1-unit increase | 1.179 (1.111–1.251) | <0.001 | 1.044 (0.980–1.113) | 0.184 | 0.960 (0.868–1.063) | 0.437 |
| <0.001 | 0.127 | 0.367 | ||||
OR, odds ratio; CI, confidence interval; Q, quartile. Model 1 adjust age and gender. Model 2 adjust Model 1+ BMI (kg/m.
Predictive value of AC and AIP for the incidence of hypertension according to BMI, age, gender, AST and ALT.
|
|
|
| ||
|---|---|---|---|---|
| AC | 0.607 | 0.598–0.616 | <0.001 | |
| AIP | 0.503 | 0.494–0.512 | 0.550 | |
| AC | 0.541 | 0.536–0.547 | <0.001 | |
| AIP | 0.496 | 0.491–0.502 | 0.181 | |
| AC | 0.612 | 0.607–0.618 | <0.001 | |
| AIP | 0.515 | 0.510–0.521 | <0.001 | |
| AC | 0.527 | 0.518–0.536 | <0.001 | |
| AIP | 0.509 | 0.500–0.518 | 0.04 | |
|
| AC | 0.545 | 0.540–0.551 | <0.001 |
| AIP | 0.496 | 0.490–0.502 | 0.148 | |
|
| AC | 0.667 | 0.659–0.674 | <0.001 |
| AIP | 0.517 | 0.509–0.525 | <0.001 | |
| AC | 0.596 | 0.589–0.603 | <0.001 | |
| AIP | 0.511 | 0.504–0.518 | 0.004 | |
| AC | 0.558 | 0.531–0.584 | <0.001 | |
| AIP | 0.516 | 0.488–0.544 | 0.263 | |
| AC | 0.613 | 0.608–0.618 | <0.001 | |
| AIP | 0.511 | 0.506–0.516 | <0.001 | |
| AC | 0.530 | 0.519–0.542 | <0.001 | |
| AIP | 0.502 | 0.490–0.514 | 0.763 |
AUC, area under curve; CI, confidence interval; AC, atherogenic coefficient; AIP, atherogenic risk of plasma; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index.
Figure 2Between-group differences in total cholesterol (TC), TG, low-density lipoprotein (LDL), high-density lipoprotein cholesterol (HDL-c), and non-HDL-c at different blood pressure levels. * Indicates Grades I–III compared with the normal group with p < 0.05. ** Indicates Grades II and III compared with Grade I with p < 0.05.
Figure 3Between-group differences in atherogenic coefficient (AC) and atherogenic risk of plasma (AIP) at different blood pressure levels. * Indicates Grades I–III compared with the normal group with p < 0.05. ** Indicates Grades II and III compared with Grade I with p < 0.05.
Figure 4The Bayesian model based on the TAN algorithm: the relationship between baseline characteristics and the incidence of hypertension (A) and the importance of predictors (B).
Figure 5The Bayesian model based on the tree augmented native (TAN) algorithm: the relationship between lipid profiles, atherosclerotic indices, and the incidence of hypertension (A) and importance of predictors (B).